Preliminary Efficacy and Safety of 8-Week Glecaprevir/Pibrentasvir in Patients with HCV Genotype 1-6 Infection and Compensated Cirrhosis: The Expedition-8 Study

被引：0

作者：

Brown, Robert S., Jr. ^{[1
]}

Hezode, Christophe ^{[2
]}

Wang, Stanley ^{[3
]}

Buti, Maria ^{[4
,5
]}

Chuang, Wan-Long ^{[6
,7
]}

Aguilar, Humberto I. ^{[8
]}

Horvath, Gabor ^{[9
]}

Rosado-Carrion, Barbara ^{[10
]}

Rodriguez-Perez, Federico ^{[11
,12
]}

Cohen, Eric ^{[3
]}

Hui, Yiran B. ^{[3
]}

Schnell, Gretja ^{[3
]}

Lin, Chih-Wei ^{[3
]}

Rodrigues, Lino, Jr. ^{[3
]}

Trinh, Roger ^{[3
]}

Mensa, Federico J. ^{[3
]}

Felizarta, Franco

机构：

[1] New York Presbyterian Hosp, Cornell Med Coll, Dept Med, Ctr Liver Desease & Transplantat, Nyc, NY USA

[2] Univ Paris Est, Hop Henri Mondor, Dept Hepatol, Paris, France

[3] Abbvie Inc, N Chicago, IL USA

[4] Hosp Univ Vall dHebron, Barcelona, Spain

[5] Vall DHebron Univ Hosp, Liver Unit, Barcelona, Spain

[6] Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Dept Internal Med, Hepatobiliary Div, Kaohsiung, Taiwan

[7] Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Hepatitis Ctr, Kaohsiung, Taiwan

[8] Louisiana Res Ctr, Shreveport, LA USA

[9] Hepatol Ctr Buda, Budapest, Hungary

[10] Ghgcpr Res Inst, Ponce, PR USA

[11] Ghwc, San Juan, PR USA

[12] Gastroenterol Sect, San Juan, PR USA

来源：

HEPATOLOGY | 2018年 / 68卷

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

715A

引用

页码：425A / 426A

页数：2

共 50 条

[31] Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Pediatric Patients with Genotypes 1-6 Chronic HCV Infection: Part 1 of the Dora Study
Jonas, Maureen M.
Squires, Robert H.
Rhee, Susan M.
Lin, Chih-Wei
Bessho, Kazuhiko
Feiterna-Sperling, Cornelia
Hierro, Loreto
Kelly, Deirdre A.
Ling, Simon C.
Strokova, Tatiana
Del Valle-Segarre, Antonio
Liu, Li
Ng, Teresa
Porcalla, Ariel
Burroughs, Margaret
Sokal, Etienne M.
HEPATOLOGY, 2018, 68 : 1347A - 1348A
[32] EXPEDITION-I: efficacy and safety of glecaprevir/pibrentasvir in adults with chronic hepatitis C virus genotype 1, 2, 4, 5 or 6 infection and compensated cirrhosis
Forns, X.
Lee, S.
Valdes, J.
Lens, S.
Ghalib, R.
Aguilar, H.
Felizarta, F.
Hassanein, T.
Hinrichsen, H.
Rincon, D.
Morillas, R.
Zeuzem, S.
Horsmans, Y.
Nelson, D.
Yu, Y.
Pilot-Matias, T.
Lin, C. -W.
Mensa, F.
JOURNAL OF HEPATOLOGY, 2017, 66 (01) : S3 - S4
[33] EXPEDITION-I: EFFICACY AND SAFETY OF GLECAPREVIR/PIBRENTASVIR IN ADULTS WITH CHRONIC HEPATITIS C VIRUS GENOTYPE 1, 2, 4, 5 OR 6 INFECTION AND COMPENSATED CIRRHOSIS
Forns, Xavier
Lee, Sam
Valdes, Joaquin M.
Lens, Sabela
Ghalib, Reem
Aguilar, Humberto
Felizarta, Franco
Hassanein, Tarek I.
Hinrichsen, Holger
Rincon, Diego
Morillas, Rosa M.
Zeuzem, Stefan
Horsmans, Yves
Nelson, David R.
Yu, Yao
Pilot-Matias, Tami
Lin, Chih-Wei
Mensa, Federico
GASTROENTEROLOGY, 2017, 152 (05) : S1061 - S1061
[34] Glecaprevir-Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection
Zeuzem, S.
Foster, G. R.
Wang, S.
Asatryan, A.
Gane, E.
Feld, J. J.
Asselah, T.
Bourliere, M.
Ruane, P. J.
Wedemeyer, H.
Pol, S.
Flisiak, R.
Poordad, F.
Chuang, W. -L.
Stedman, C. A.
Flamm, S.
Kwo, P.
Dore, G. J.
Sepulveda-Arzola, G.
Roberts, S. K.
Soto-Malave, R.
Kaita, K.
Puoti, M.
Vierling, J.
Tam, E.
Vargas, H. E.
Bruck, R.
Fuster, F.
Paik, S. -W.
Felizarta, F.
Kort, J.
Fu, B.
Liu, R.
Ng, T. I.
Pilot-Matias, T.
Lin, C. -W.
Trinh, R.
Mensa, F. J.
NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (04): : 354 - 369
[35] EFFICACY AND SAFETY OF 8-WEEK GLECAPREVIR/PIBRENTASVIR FOR THE TREATMENT OF PATIENTS WITH ACUTE HEPATITIS C: A SINGLE-ARM RETROSPECTIVE STUDY
Pol, Stanislas
Thompson, Alexander J.
Collins, Michelle
Venier, Elisa
Cotte, Laurent
Laguno, Monserrat
Mera, Jorge Raul
Reiberger, Thomas
Burroughs, Margaret
Semizarov, Dimitri G.
Iacob, Alexandru M.
Welhaven, Anne
Fredrick, Linda
Doyle, Joseph S.
HEPATOLOGY, 2024, 79 (02) : E81 - E82
[36] Real-World Clinical Practice Use of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve Patients with Compensated Cirrhosis
Pietro Lampertico
Stefan Mauss
Marcello Persico
Stephen T. Barclay
Steven Marx
Kristina Lohmann
Mark Bondin
ZhenZhen Zhang
Fiona Marra
Pamela S. Belperio
Heiner Wedemeyer
Steven Flamm
Advances in Therapy, 2020, 37 : 4033 - 4042
[37] Effectiveness of 8-Week Glecaprevir/Pibrentasvir for Treatment-Naïve, Compensated Cirrhotic Patients with Chronic Hepatitis C Infection
Steven L. Flamm
Jens Kort
Steven E. Marx
John Strezewski
Douglas E. Dylla
Bruce Bacon
Michael P. Curry
Naoky Tsai
Nicole Wick
Advances in Therapy, 2020, 37 : 2267 - 2274
[38] EFFICACY OF 8 WEEKS GLECAPREVIR/PIBRENTASVIR IN ROUTINE CARE OF PATIENTS WITH CIRRHOSIS AND NON GENOTYPE 3 INFECTION.
Marra, Fiona
Boyle, Alison
Peters, Erica
Morris, Judith
Priest, Matthew
Mcdonald, Natasha
Barclay, Stephen T.
HEPATOLOGY, 2019, 70 : 957A - 958A
[39] Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients with HCV Genotype 5 or 6 Infection: Final Results of the Endurance-5,6 Study
Lee, Samuel S.
Asselah, Tarik
Yao, Betty
Tuan Nguyen
Wong, Florence
Mahomed, Adam
Lim, Seng Gee
Abergel, Armand
Sasadeusz, Joe
Gane, Edward J.
Zadeikis, Neddie
Krishnan, Preethi
Zhang, Zhenzhen
Porcalla, Ariel
Alves, Katia
Mensa, Federico J.
Kinh Nguyen
HEPATOLOGY, 2018, 68 : 426A - 427A
[40] Efficacy and safety of glecaprevir/pibrentasvir in renally-impaired patients with chronic hepatitis C virus genotype 1-6 infection
Persico, M.
Flisiak, R.
Abunimeh, M.
Sise, M.
Park, J. Y.
Kaskas, M.
Bruchfeld, A.
Woerns, M. -A.
Aglitti, A.
Xue, Z.
Rullman, J.
Pocalla, A.
Lawitz, E.
JOURNAL OF HEPATOLOGY, 2018, 68 : S292 - S292

← 1 2 3 4 5 →